KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Castle Biosciences (CSTL) Amortization - Intangibles (2021 - 2026)

Castle Biosciences' Amortization - Intangibles history spans 5 years, with the latest figure at $2.3 million for Q4 2025.

  • On a quarterly basis, Amortization - Intangibles rose 8.38% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.6 million, a 199.49% increase, with the full-year FY2025 number at $34.8 million, up 213.69% from a year prior.
  • Amortization - Intangibles hit $2.3 million in Q4 2025 for Castle Biosciences, down from $2.3 million in the prior quarter.
  • Over the last five years, Amortization - Intangibles for CSTL hit a ceiling of $20.1 million in Q1 2025 and a floor of $300000.0 in Q2 2021.
  • Historically, Amortization - Intangibles has averaged $2.9 million across 5 years, with a median of $2.2 million in 2024.
  • The widest YoY moves for Amortization - Intangibles: up 794.53% in 2025, down 12.73% in 2025.
  • Tracing CSTL's Amortization - Intangibles over 5 years: stood at $958000.0 in 2021, then skyrocketed by 134.76% to $2.2 million in 2022, then increased by 2.85% to $2.3 million in 2023, then fell by 9.21% to $2.1 million in 2024, then rose by 8.38% to $2.3 million in 2025.
  • Business Quant data shows Amortization - Intangibles for CSTL at $2.3 million in Q4 2025, $2.3 million in Q3 2025, and $2.0 million in Q2 2025.